Join to View Full Profile
353 Lexington AvenueSuite 1605New York, NY 10016
Phone+1 240-389-2381
Fax+1 240-389-2381
Dr. Lener is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Marc Lener is a psychiatrist based in New York, NY. He completed his medical education at George Washington University School of Medicine and Health Sciences, followed by a psychiatry residency at Icahn School of Medicine at Mount Sinai from 2011 to 2015. He also completed a fellowship at the National Institute of Mental Health from 2015 to 2018. His areas of experience include post-traumatic stress disorder, attention-deficit/hyperactivity disorder, depressive disorders, anxiety disorders, and behavioral health. Dr. Lener has contributed to several publications focusing on the effects of ketamine in depressive disorders, some of which have been cited multiple times in other works.
Education & Training
Clinical Center at the National Institutes of HealthFellowship, National Institute of Mental Health, 2015 - 2018
Icahn School of Medicine at Mount Sinai ProgramResidency, Psychiatry, 2011 - 2015- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2011 - 2015
George Washington University School of Medicine and Health SciencesClass of 2011
University of PennsylvaniaB.A., Biological Basis of Behavior, 1996 - 2000
Certifications & Licensure
NY State Medical License 2013 - 2027
CT State Medical License 2025 - 2026
MD State Medical License 2015 - 2026
CO State Medical License 2021 - 2023
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 19 citationsThe effects of ketamine on typical and atypical depressive symptoms.Lawrence Park, David A. Luckenbaugh, S. J. Pennybaker, Matthew Hopkins, Ioline D. Henter
Acta Psychiatrica Scandinavica. 2020-11-01 - 26 citationsNeurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.Lawrence Park, Maura L. Furey, Allison C. Nugent, Cristan Farmer, Jessica Ellis
The International Journal of Neuropsychopharmacology. 2019-01-01 - 49 citationsAcute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.Bashkim Kadriu, Philip W. Gold, David A. Luckenbaugh, Marc S. Lener, Elizabeth D. Ballard
Molecular Psychiatry. 2018-07-01
Journal Articles
- Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat DepressionLener MS, Kadriu B, Zarate C, Drugs, 2/14/2017
Authored Content
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
Professional Memberships
- Member
- Society of Biological PsychiatryMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
